Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

AUGUST 14, 2021

After acquiring the patented Gelpell technology through its acquisition of Satipharm in March, Cann is now looking to resume an internal development program with the aim of securing TGA approval for a Schedule 3 CBD product by the end of 2022.

CBD 105

CBD Clinical Trials Programs Medicine 105

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. The live webcast can be accessed here and on the investor page of Marinus’ website. Conference Call and Webcast Details.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. While its psilocybin and MDMA trials progress, the company is expanding its psychedelics research laboratory.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

NOVEMBER 1, 2021

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 135, 2022 (Forthcoming) , Available at SSRN: [link] or [link].

Research and Development 52

Research and Development Law Clinical Trials Therapy 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

APRIL 2, 2022

Bienstar Plans To Build LATAM’s First Network of Integrative Mental Health Clinics. TORONTO, ON / ACCESSWIRE / March 31, 2022 / Novamind Inc. Upon signing a definitive agreement, Bienstar will have access to a broad patient base in Brazil-the largest market in Latin America with 215 million people.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. To access a complete photo gallery of this historic grow, please click here.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

FEBRUARY 10, 2022

A look at key research and clinical trials that were published in 2021, with analysis of themes like microdosing and SSRI interactions. In the final section we share the key trends we will be following as we look ahead to 2022. Access the PDF here. and Canada.

Clinical Trials 52

Clinical Trials Microdosing Pharmaceutical Policy 52

The Cannigma

AUGUST 14, 2022

A 2022 rodent study found that cannabis significantly “increased functional coupling” in the RAS of male mice (but not female mice, oddly enough). If you don’t have access to lab reports, smell the weed before you buy it. The RAS is a sensitive piece of equipment – when it’s under or overstimulated, focusing can be difficult.

Terpenes 128

Terpenes Strains THC Oil 128

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). May 11, 2022 02:00 AM Eastern Daylight Time. Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

FEBRUARY 9, 2022

09, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: The application includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients.

Research and Development 52

Research and Development Clinical Trials Treatment Patients 52

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. Draft Law of Ukraine. ARV (revised). REFERENCE to the EU acquis. explanatory note. Comparative table. LAW OF UKRAINE.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. This report from Vice on the back of new research released by the University of Sydney. Here’s the Uni of Sydney press release. First academic study of national medicinal cannabis data.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

SEPTEMBER 2, 2021

ADCL will serve as prime contractor with subcontractor CLEARED4’s health verification platform to be used for appointments, sample tracking, reporting, program management, and mobile access pass visibility. Hayward, president and CEO of Applied DNA. Food and Drug Administration (U.S.

Clinical Trials 76

Clinical Trials Therapy Research and Development Collective 76

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

NOVEMBER 23, 2021

135, 2022 (Forthcoming). Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Read more at [link]. Mason Marks.

Law 52

Law Research and Development Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 4, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

FEBRUARY 3, 2022

The number of patients approved for the use of medical cannabis in Israel has increased steadily, reaching over 100,000 in January 2022. We will soon also produce the first batches for upcoming clinical trials of MediCane later in the year.”.

Clinical Trials 40

Clinical Trials Research and Development Packaging Oil 40

Cannabis Law Report

DECEMBER 7, 2021

A full report of the anonymized, aggregate findings will be released in early 2022. Initial findings indicate a significant number of participants experienced clinically meaningful improvements, meaning they realized distinct and palpable improvements in quality of life through improvements in the respective health outcomes studied.

Clinical Trials 40

Clinical Trials CBD Data Sleep 40

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 40

Clinical Trials Research and Development Sleep Cannabinoids 40

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

SpeedWeed

AUGUST 4, 2021

I want to be a part of the change that sees patients become able to access quality cannabis medicines and to change lives. We will be investing heavily in research and development and clinical trials to develop a full range of medicines, ready for registration and marketing authorization in Australia and Europe. .

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Cannabis Law Report

NOVEMBER 29, 2021

The potential real-life impact – keeping in mind that these data were generated under stringent clinical trial conditions and without any tailoring to the specific needs of the individual – could be even more transformative for those patients suffering from TRD. TRD is just the beginning.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Programs shall train students on how to proactively make psilocybin services accessible to people with disabilities.

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

MAY 1, 2022

We note nearly half (49%) of the respondents to your Community Interest Survey indicated that their interest in accessing psilocybin under Measure 109 was for spiritual purposes. In other words, the agency is empowered to adopt rules that promote other values such as the free exercise of religion or the accessibility of psilocybin services.

Safety 52

Safety History Programs Clinical Trials 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 40

Therapy Research and Development Business Access 40

Cannabis Law Report

DECEMBER 21, 2021

The school’s new location will be opening up in Q1 of 2022 to further ease the shortage and tension of much-needed healthcare workers. Yet, more than half of the people in the least developed countries lack access to electricity. Digital Accessibility Compliance – More than 1 billion people live with a disability.

Research and Development 40

Research and Development Supply Chain Data Business 40

Cannabis Law Report

MAY 14, 2022

13 May 2022. One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. Canpain is planned to run for three years and aims to conduct clinical trials involving up to 5,000 patients suffering from chronic pain.

Access 52

Access CBD Research and Development Medicine 52